Personalised medicine for cystic fibrosis: Treating the basic defect

European Respiratory Review

Volumn 22, Issue 127, 2013, Pages 3-5

  Elborn, J Stuart ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DORNASE ALFA; IVACAFTOR; PANCREAS ENZYME; TOBRAMYCIN;

ASTHMA; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE; EDITORIAL; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LUNG CLEARANCE; PERSONALIZED MEDICINE; SWEAT TEST;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; MUTATION; PATIENT SELECTION; PHENOTYPE;

EID: 84874689513     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00008112     Document Type: Editorial

References (19)

1. Jain KK. Personalized medicine. Curr Opin Mol Ther 2002; 4: 548-558.
2. Sykiotis GP, Kalliolias GD, Papavassiliou AG. Pharmacogenetic principles in the Hippocratic writings. J Clin Pharmacol 2005; 45: 1218-1220.
3. Jain KK, ed. Textbook of Personalised Medicine. New York, Springer, 2009.
4. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007; 6: 287-293.
5. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res 2009; 154: 277-287.
6. Olopade OI, Grushko TA, Nanda R, et al. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 2008; 14: 7988-7999.
7. Camarero J, Ruiz S. Cancer immunotherapy products: regulatory aspects in the European Union. Hum Vaccin Immunother 2012; 8: 1354-1359.
8. Tse SM, Tantisira K, Weiss ST. The pharmacogenetics and pharmacogenomics of asthma therapy. Pharmacogenomics J 2011; 11: 383-392.
9. Portelli M, Sayers I. Genetic basis for personalized medicine in asthma. Expert Rev Respir Med 2012; 6: 223-236.
10. Hall IP, Sayers I. Pharmacogenetics and asthma: false hope or new dawn? Eur Respir J 2007; 29: 1239-1245.
11. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352: 1992-2001.
12. Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 2011; 183: 1463-1471.
13. Amaral MD. Targeting CFTR: how to treat cystic fibrosis by CFTR- repairing therapies. Curr Drug Targets 2011; 12: 683-693.
14. De Boeck K, Derichs N, Fajac I, et al. New clinical diagnostic procedures for cystic fibrosis in Europe. J Cyst Fibros 2011; 10: Suppl. 2, S53-S66.
15. McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 2006; 130: 1441-1447.
16. Hall IP. Stratified medicine: drugs meet genetics. Eur Respir Rev 2013; 22: 53-57.
17. Derichs N. Targeting a genetic defect: cystic fibrosis transmem- brane conductance regulator modulators in cystic fibrosis. Eur Respir Rev 2013; 22: 58-65.
18. Sermet-Gaudelus I. Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation. Eur Respir Rev 2013; 22: 66-71.
19. Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001; 19: 491-496.